Friday 23 December 2022

6 Sanofi India Update

Reasons for buying:

Market Cap: ₹13,602 Cr (Bluechip stock)

Debt to Equity: 0.05

Return on Equity 5Y Avg: 23.83%

EPS - 5Y Growth: 29.46%

Price-earnings to growth (5Y): 0.47

5Y RoE Consistency - Sustained without losing 20% in any year

Buy date: 4-Apr-2022

Qty: 1 Buy Price: ₹7,400 Buy EPS: 410.06

Buy date: 10-May-2022

Qty: 1 Buy Price: ₹6,660 Buy EPS: 450.22

Buy date: 23-Sep-2022

Qty: 1 Buy Price: ₹5,908.95 Buy EPS: 425.08

The yield is 3% and paid dividend continues with good fundamentals so added more.

Buy date: 23-Dec-2022

Qty: 12 Price: ₹5833.85 EPS₹251.88

Will continue to add when a stock falls 10% as long as the ratios remain the same. The stock would take a long time to pay, it lost 20% since I bought it in April.

Sanofi India is a drug manufacturing company that focuses on a range of therapeutic areas, including Diabetes, Cardiology, Consumer Healthcare, Hospitals, Central Nervous systems, and Anti-Histamines. The company's diabetes presence includes oral anti-diabetic products and insulin. The consumer healthcare area also maintains a nutraceutical portfolio. The company's export markets include Germany, the U.K., Australia, and Russia. The company utilizes strategic partnerships as a component of its growth strategy.

No comments:

Post a Comment